A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Inclusion Criteria:

• Participants must have completed study CNMAu8.201.
• Able to understand and give written informed consent.

Exclusion Criteria:

• Lack of treatment compliance during participation in the CNMAu8.201 (VISIONARY-MS)study.
• Positive pregnancy test.
• Any history of previous malignancy, with the exception of basal cell carcinoma of theskin or in situ carcinoma of the cervix, post documented full resections, with cleanmargins.
• Based on the Investigator's judgment, any concurrent chronic or acute illness orunstable medical condition that could confound the results of safety assessments,increase risk to the participant, or lead to difficulty complying with the protocol;any untreated or unstable psychiatric disease including depression, bipolar andpsychosis.
• Participant is considered a suicide risk in the opinion of the Investigator, haspreviously made a suicide attempt, or is currently demonstrating active suicidalideation. Following clinical and serology sample analysis conducted at the end-of-study visit forCNMAu8.201 (VISIONARY-MS), participants may be removed from this long term extension studyif any of the following criteria are met, at the discretion of the Medical Monitor and/orSponsor's Medical Representative:
• Positive serology for viral hepatitis B and/or C and/or human immunodeficiency virus (HIV).
• Abnormal liver function tests (aspartate aminotransferase [ASAT] or alanineaminotransferase [ALAT] > 2x upper limit of normal range (ULN) or total bilirubin > 2xULN or alkaline phosphatase (AP) > 3x ULN).
• Participants with clinically significant hepatic or renal dysfunction or clinicallaboratory findings that would limit the interpretability of change in liver or kidneyfunction (e.g., glomerular filtration rate < 40 mL/min [based on creatinine clearanceaccording to Cockcroft-Gault equation]), or those with low platelet counts (<150 x 109per liter) or eosinophilia (absolute eosinophil count of ≥500 eosinophils permicroliter) at the EOS visit for CNMAu8.201 (Visionary-MS).